article thumbnail

Wake Network Retains CRO Santé Cannabis to Conduct Clinical Trials in Psilocybin Therapies

Cannabis Law Report

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. This engagement will build on the strong foundation on Santé, having treated more than 10,000 patients since 2014 under a real-world data protocol.

article thumbnail

European Regulatory Lead MAPS PBC Santa Cruz, CA

Cannabis Law Report

The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. Founded in 2014, MAPS PBC is a Public Benefit Corporation that prioritizes public benefit over profit. European Regulatory Lead Executive Summary. Key Responsibilities.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Press Release: Global Wellness Signs Definitive Agreement with Cannvalate Australia

Cannabis Law Report

This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. 2014; 7: 115-124. (“Shanti”), and all its assets focused on psychedelic MDMA-based drug development. billion in 2030.

article thumbnail

Perez Hilton and Centuria Foods Launch New CBD Gummies, My True 10

Cannabis Law Report

The tasty, and fast acting My True 10 CBD watermelon flavored gummies are different from many products in the CBD category as they are backed by extensive research and clinical trials. Not all CBD is made equal, as seen with the high-quality ingredients and thoughtful innovation in the My True 10 gummies.

Food 81
article thumbnail

MAPS: Regulatory Publishing Specialist – Remote Position Regulatory Affairs · Any City, Any State, California

Cannabis Law Report

Founded in 2014, MAPS PBC is a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS) a 501(c)(3) nonprofit. 2-3 years of relevant experience in clinical trials, research methods, or statistical design and analysis. Experience working for a clinical study Sponsor.

article thumbnail

Oxford Cannabinoid Technologies Holdings plc – Pre-Close Trading Update; US OTC QB Market Application & Notice of 2021 Final Results

Cannabis Law Report

At the end of the programme, Evotec will provide the Company with a submission-ready regulatory document which will be used for submissions to regulatory agencies, as well as drug-batch approved and ready for First Time in Human clinical trials. The planning phase has been completed and “wet-work” initiated as per proposed timelines.

article thumbnail

Cannabis Corporate Virus Spreads Across The Pond … Oxford Cannabinoid Technologies’ Shares Fall A Further 20% As Chairman Stands Down Following Market Rule Breach

Cannabis Law Report

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018). OCT is conducting pre-clinical testing and development with pre-clinical trials scheduled for 2022. A PDMR form is set out below.